Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Vaxcyte Inc. (NASDAQ:PCVX) closed its public offering of the sale of 12.65 million shares of the company’s common stock at $50 per share, raising $632.5 million in gross proceeds in the process. The offering included the full exercise of the underwriters’ option to purchase an additional 1.65 million shares at the public offering price, less underwriting discounts and commissions.

Meanwhile, on January 23, Cantor Fitzgerald reiterated its Overweight rating on Vaxcyte Inc. (NASDAQ:PCVX), noting that the company’s clinical pipeline is progressing according to schedule. The analyst projected that the topline readout from Vaxcyte’s Phase 3 OPUS-1 non-inferiority trial is expected in the fourth quarter of 2026, with an adult Biologics License Application filing planned for 2027. The firm also projected the release of results for the company’s OPUS-2 and OPUS-3 studies to be released in the first half of 2027.

Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating

Vaxcyte Inc. (NASDAQ:PCVX) develops vaccines for infectious diseases, focusing on conjugate and protein-based vaccines delivered through a platform based on cell-free protein synthesis technology.

While we acknowledge the risk and potential of PCVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PCVX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 11 Best Stocks Under $3 to Buy Right Now and  10 Best High-Upside Materials Stocks to Buy

Disclosure: None. This article is originally published at Insider Monkey.